Clinical trial
A Phase II Study of Paclitaxel Polymeric Micelles Combined With Ivonescimab in Patients With Recurrent or Refractory Small Cell Lung Cancer After Failure of Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Therapy
NCT07819591 is registered in ClinicalTrials.gov with Shaodong Hong as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Paclitaxel Polymeric Micelles Combined With Ivonescimab in Patients With Recurrent or Refractory Small Cell Lung Cancer After Failure of Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Therapy
- Lead sponsor
- Shaodong Hong
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- October 1, 2026
- Completion date
- December 1, 2028
- Enrollment
- 47 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
sclc, recurrent